If PARP inhibitors can promote canonical Wnt/β-catenin signaling by increasing the levels of the Wnt3A ligand, then the diminished responsiveness to canonical Wnt signaling in BRCA2-null ovarian cancer cells may also possibly contribute to the improved survival observed in BRCA2-mutant patients. This evidence concerns the gene WNT3A and ovarian cancer.